## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.92 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($87.25)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. TD Cowen reaffirms Boston Scientific stock rating with $115 price target**
- Source: Investing.com | 20251211T160746 | Bullish | Relevance: 100%
-  TD Cowen has reiterated its Buy rating on Boston Scientific (NYSE:BSX) with a $115 price target, naming it the firm's "Best Idea for 2026." The research firm expressed confidence in Boston Scientificâ€™s long-range plan, projecting strong organic sales growth, operating margin expansion, and double-digit annual EPS growth, citing the company's consistent track record and scarcity value. Key product drivers like Farapulse and Watchman are expected to fuel continued growth in the medical devices sector.

**2. Boston Scientific announces positive coverage policy for Intracept procedure**
- Source: Med-Tech Insights | 20251211T135355 | Bullish | Relevance: 99%
-  Boston Scientific announced that Health Care Service Corporation (HCSC), a major U.S. commercial health insurer, now covers the Intracept Procedure for eligible patients with chronic vertebrogenic low back pain. This policy, effective December 1, 2025, extends coverage to over 26 million people nationwide, acknowledging the clinical value and expanding access to this FDA-cleared, minimally invasive treatment. The Intracept Procedure is described as the only therapy specifically designed to target vertebrogenic pain with proven safety, effectiveness, and durability through long-term clinical studies.

**3. Boston Scientific Sustains Momentum in the PFA Market: What's Next?**
- Source: TradingView | 20251211T130808 | Bullish | Relevance: 99%
-  Boston Scientific is maintaining a leading position in the Pulsed Field Ablation (PFA) market, particularly with its FARAPULSE technology, which continues to show strong adoption and positive clinical outcomes for treating atrial fibrillation. The company is actively investing in innovation to grow its market share in both AF and non-AF segments, while competitors like Abbott and Medtronic are also advancing their PFA and surgical robotic technologies. Despite a slight underperformance in stock price compared to the industry, Boston Scientific's earnings estimates are trending upwards, indicating a positive outlook.

**4. Can Boston Scientific (BSX) Sustain Its Momentum As Minimally Invasive Care Becomes Mainstream?**
- Source: Simply Wall Street | 20251211T030801 | Bullish | Relevance: 99%
-  Boston Scientific has demonstrated strong growth with 23% revenue increase and tripled EPS over five years, driven by demand for its minimally invasive devices. The company is well-positioned due to aging populations and rising chronic diseases, with a narrative projecting $25.4 billion revenue and $4.8 billion earnings by 2028, suggesting a significant upside. However, potential risks include margin pressure from tariffs and regulatory setbacks.

**5. Boston Scientific Stock Is Dropping: Reasons Behind BSX Sell-Off**
- Source: EBC Financial Group | 20251210T080748 | Neutral | Relevance: 99%
- Boston Scientific's stock (BSX) is undergoing a significant pullback, dropping about 15.5% from its 52-week high, despite a strong five-year return. This sell-off is attributed to profit-taking, a premium valuation reset, the impact of higher interest rates on growth stocks, and a technical breakdown that has triggered further selling. Fundamentally, the company remains robust with strong Q3 2025 earnings and raised full-year guidance, suggesting the decline is more about market sentiment and valuation adjustments rather than business weakness.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $132 | $132 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 9.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $136.0B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 26.5 |
| Current P/E | 30.2 |
| YoY Growth | 14.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -4.8% to -8.7% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 12.7pp (needs >4.0% for momentum thesis). AM_20 at -6.7% indicates price below own 20MA trend. Underperforming sector by 6.4pp, stock-specific weakness. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram bearish (-0.90), momentum weakening. RSI oversold at 30, potential bounce setup.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -8.68% (CS: 2) | Weak |
| RSI_14 | 29.7 | Oversold |
| MACD Histogram | -0.90 | Bearish |
| vs SMA20 | 0.933x | Below |
| vs SMA50 | 0.928x | Below |
| vs SMA200 | 0.906x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $91.75
- **Stop Loss:** $87.25 (4.9% risk)
- **Target:** $100.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 306
- **Position Value:** $28,075.50
- **Portfolio %:** 28.08%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*